Message #6 From:
NewsBot Date: August 8, 2005 11:00:00 PM
XNOM News Webalert: Xenomics CEO Randy White to Field Questions Today in Online Discussion with American Assoc. of Clinical Chemistry; CEO to Discuss Company's Commercialization of Proprietary Diagnostic Platform Technology for Biomedical Marketplace
NEW YORK--(BUSINESS WIRE)--Aug. 9, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced that CEO Dr. Randy White will be leading an online, interactive discussion at 1 PM EST today to discuss the science behind the Company's breakthrough Transrenal-DNA technology platform. He will also expand on the Company's efforts to develop a new category of safer, more expedient and highly accurate medical diagnostic tests for wide-ranging health conditions, from HIV to cancer, to prenatal tests for fetal genetic abnormalities such as Down syndrome.
The program is part of an ongoing public education series, "Expert Access," produced monthly by the American Association for Clinical Chemistry (AACC), the premier trade association dedicated to encouraging the study and practice of clinical chemistry and molecular diagnostics. Today's hour-long segment will feature Dr. White in an interactive discussion about the exciting scientific potential of Transrenal-DNA (Tr-DNA), a proprietary technology platform that Xenomics is developing into a suite of noninvasive, but highly accurate and diagnostically powerful medical tests for disease and genetic conditions. These tests could revolutionize medical testing practices across several multi-billion dollar global commercial healthcare markets.
The public is encouraged to ask questions of Dr. White or submit comments during the discussion. To participate, please visit: http://www.aacc.org/access/molecular/index.asp, and click on "view presentation."
About American Association for Clinical Chemistry
The American Association for Clinical Chemistry (AACC) is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry, molecular diagnostics and other clinical laboratory science-related disciplines. For more information, visit http://www.aacc.org.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing, a newly allowed European patent for prenatal genetic testing and nine pending U.S. and European patent applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
